Aradigm is actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease.

Since 1991, the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products. This team pioneered the AERx® iDMS pulmonary delivery of insulin that was used in Phase 3 clinical trials conducted by its partner Novo Nordisk. With the depth of experience and expertise in inhalation delivery, Aradigm is uniquely positioned to develop a portfolio of its own products to treat patients with severe respiratory diseases. The current pipeline includes products that are being developed by Aradigm, or in partnerships with others, for the treatment of cystic fibrosis, bronchiectasis* and inhalation anthrax. The company is also investigating the use of its technology for tobacco smoking cessation therapy.

* If you would like to see a video explaining what bronchiectasis is, please, click on this icon: